HDV2 O‐09: REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian Patients with chronic HBV/HDV co‐infection

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|S2|5-6

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.S2, 2015-06, pp. : 5-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FREE PAPER B O‐05: Sorafenib interferes with signaling events important for NTCP‐mediated HBV/HDV uptake

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 3-3

John Wiley & Sons Inc

Access to resources Recommend Favorite

O‐12: Study of the super‐infection by Hepatitis B Virus (HBV) and Hepatitis Delta Virus (HDV) in the HepaRG cell model

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 7-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 140-147

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 9, 2010-09 ,pp. : 1498-1506

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

By  

Intervirology, Vol. 50, Iss. 3, 2007-01 ,pp. : 161-165

Karger

Access to resources Recommend Favorite